APLS
Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. insider trading
Apellis Pharmaceuticals, Inc. files with the SEC as a Pharmaceutical Preparations company headquartered in Waltham, MA. Every time one of its executives or directors buys or sells the stock, the filing appears here the moment it reaches the SEC — with grants and option exercises set apart from the trades that cost the insider their own money.
From SEC filings
Recent APLS insider transactions
Apellis Pharmaceuticals, Inc.'s insiders made no open-market purchases or sales in the company's most recent Form 4 filings — those filings are share grants, option exercises and dispositions back to the issuer, which are compensation rather than decisions. That absence is itself worth knowing: nobody at APLS spent or raised their own money in the market over this stretch. Two years of open-market trades are below.
SEC Form 4 data, Q3 2024 to Q2 2026
APLS insider trading by quarter
Between Jul 01, 2024 and Jun 30, 2026, 12 insiders traded APLS on the open market: 0 purchases and 95 sales worth $21.6M, 16 of the sales pre-scheduled under a 10b5-1 plan. In the last four quarters alone: 0 purchases and 45 sales ($17M), by 9 insiders.
| Quarter | Bought | Sold | Insiders |
|---|---|---|---|
| Q2 2026 | — | — | |
| Q1 2026 | — | −$2.6M25 sales | |
| Q4 2025 | — | −$1.4M5 sales · all on a plan | |
| Q3 2025 | — | −$13.1M15 sales · 10 on a plan | |
| Q2 2025 | — | −$93.9K1 sale · all on a plan | |
| Q1 2025 | — | −$2.9M43 sales | |
| Q4 2024 | — | −$173.3K2 sales | |
| Q3 2024 | — | −$1.4M4 sales |
- Largest sale
- −$4.9M of APLS by Francois Cedric (Chief Executive Officer · Director) on Aug 27, 2025.
Open-market transactions through Jun 30, 2026most recent first
DeLong Mark Jeffrey
Chief Business & Strat Officer
−$8.2K
Feb 11, 2026
368 sh · $22.15
Francois Cedric
Chief Executive Officer · Director
−$592K
Jan 22, 2026
27,192 sh · $21.77
Sullivan Timothy Eugene
Chief Financial Officer
−$223.9K
Jan 22, 2026
10,287 sh · $21.77
Watson David O.
General Counsel
−$170.5K
Jan 22, 2026
7,832 sh · $21.77
Nicholson Nur
Chief Technical Officer
−$168.2K
Jan 22, 2026
7,725 sh · $21.77
Deschatelets Pascal
Chief Scientific Officer
−$129.1K
Jan 22, 2026
5,928 sh · $21.77
DeLong Mark Jeffrey
Chief Business & Strat Officer
−$73.4K
Jan 22, 2026
3,371 sh · $21.77
Baumal Caroline
Chief Medical Officer
−$60.9K
Jan 22, 2026
2,797 sh · $21.77
Chopas James George
VP/Chief Accounting Officer
−$44.9K
Jan 22, 2026
2,064 sh · $21.77
Francois Cedric
Chief Executive Officer · Director
−$161.9K
Jan 20, 2026
8,182 sh · $19.79
Sullivan Timothy Eugene
Chief Financial Officer
−$57.2K
Jan 20, 2026
2,892 sh · $19.79
Watson David O.
General Counsel
−$49K
Jan 20, 2026
2,475 sh · $19.79
Nicholson Nur
Chief Technical Officer
−$43.6K
Jan 20, 2026
2,203 sh · $19.79
Baumal Caroline
Chief Medical Officer
−$37.2K
Jan 20, 2026
1,882 sh · $19.79
DeLong Mark Jeffrey
Chief Business & Strat Officer
−$26.4K
Jan 20, 2026
1,334 sh · $19.79
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 11, 2026 | DeLong Mark JeffreyChief Business & Strat Officer | 368 | $22.15 | −$8.2K |
| Jan 22, 2026 | Francois CedricChief Executive Officer · Director | 27,192 | $21.77 | −$592K |
| Jan 22, 2026 | Sullivan Timothy EugeneChief Financial Officer | 10,287 | $21.77 | −$223.9K |
| Jan 22, 2026 | Watson David O.General Counsel | 7,832 | $21.77 | −$170.5K |
| Jan 22, 2026 | Nicholson NurChief Technical Officer | 7,725 | $21.77 | −$168.2K |
| Jan 22, 2026 | Deschatelets PascalChief Scientific Officer | 5,928 | $21.77 | −$129.1K |
| Jan 22, 2026 | DeLong Mark JeffreyChief Business & Strat Officer | 3,371 | $21.77 | −$73.4K |
| Jan 22, 2026 | Baumal CarolineChief Medical Officer | 2,797 | $21.77 | −$60.9K |
| Jan 22, 2026 | Chopas James GeorgeVP/Chief Accounting Officer | 2,064 | $21.77 | −$44.9K |
| Jan 20, 2026 | Francois CedricChief Executive Officer · Director | 8,182 | $19.79 | −$161.9K |
| Jan 20, 2026 | Sullivan Timothy EugeneChief Financial Officer | 2,892 | $19.79 | −$57.2K |
| Jan 20, 2026 | Watson David O.General Counsel | 2,475 | $19.79 | −$49K |
| Jan 20, 2026 | Nicholson NurChief Technical Officer | 2,203 | $19.79 | −$43.6K |
| Jan 20, 2026 | Baumal CarolineChief Medical Officer | 1,882 | $19.79 | −$37.2K |
| Jan 20, 2026 | DeLong Mark JeffreyChief Business & Strat Officer | 1,334 | $19.79 | −$26.4K |
From SEC's quarterly Form 3, 4 and 5 data sets: code P purchases and code S sales of common stock, by the date the trade happened. Where a fund and the people who control it each report the same block, it is counted once. Trades made in the last days of Q2 2026 but filed after it closed arrive with SEC's next quarterly release.
Apellis Pharmaceuticals, Inc. company record
- SEC industry classification
- Pharmaceutical Preparations
- Headquarters
- Waltham, MA
- Incorporated in
- DE
- SEC Central Index Key
- 0001492422
Sourced from this company's own SEC submissions record. The industry label is SEC's Standard Industrial Classification, which is more specific than the Health Care sector shown above.
After insiders bought APLS
What the stock actually did in the 90 days following each open-market purchase
Don't check APLS — let it ping you
Get told the moment an insider moves on APLS
Pro watches Apellis Pharmaceuticals, Inc. for you and sends a Telegram ping within moments of a Form 4 clearing EDGAR — a C-suite open-market buy, a cluster, a 10b5-1 regime break — long before it reaches the press. Add APLS to a watchlist, see each mover's benchmark-measured track record and which legendary funds hold it, and read the full filing history instead of the last 72 hours.
The live dashboard is free to open. Alerts, watchlists, full filing history and each mover's benchmark-measured track record are Pro. Monitoring, not advice.
How to read APLS insider activity
- Open-market purchase (code P)
- An insider spending their own money at market price. This is the only buy code that reliably carries signal — it is a decision, not compensation.
- Grants and option exercises (codes A, M)
- Scheduled compensation. Most "insider buying" headlines are really this, which is why InsiderPulse weights it at a fraction of a real purchase.
- Cluster buy
- Two or more different insiders buying on the open market in the same window. One executive buying can mean anything; three is much harder to explain away.
Other Health Care tickers
Questions
- Have APLS insiders bought or sold stock recently?
- No open-market purchases or sales by Apellis Pharmaceuticals, Inc. insiders appear in the Form 4 filings scanned for this page. Grants, option exercises and tax withholding are not counted as trades.
- How much APLS stock have insiders bought and sold in the last two years?
- Between Jul 01, 2024 and Jun 30, 2026, 12 Apellis Pharmaceuticals, Inc. insiders made no open-market purchases and 95 sales worth $21.6M. 16 of the sales were pre-scheduled under a Rule 10b5-1 plan. In the four quarters to Jun 30, 2026: no purchases and 45 sales ($17M). The largest sale was Francois Cedric selling $4.9M on Aug 27, 2025.
- Where does APLS insider trading data come from?
- From the Form 4 filings Apellis Pharmaceuticals, Inc.'s officers, directors and 10% owners must send the SEC within two business days of a trade. Each row on this page links to its original filing on SEC EDGAR. Share grants and option exercises are kept apart from open-market purchases and sales, because only the latter cost the insider their own money.
Get the free Insider Brief
Each weekday evening: the day's biggest open-market insider buys, cluster formations and 10b5-1 plan breaks — in plain English, with grants and routine vesting stripped out. Honest about what the data can and cannot say.